ATE556051T1 - Neues heteroarylderivat - Google Patents
Neues heteroarylderivatInfo
- Publication number
- ATE556051T1 ATE556051T1 AT04747746T AT04747746T ATE556051T1 AT E556051 T1 ATE556051 T1 AT E556051T1 AT 04747746 T AT04747746 T AT 04747746T AT 04747746 T AT04747746 T AT 04747746T AT E556051 T1 ATE556051 T1 AT E556051T1
- Authority
- AT
- Austria
- Prior art keywords
- optionally substituted
- heteroaryl derivative
- heteroaryl
- single bond
- new heteroaryl
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003274684 | 2003-07-15 | ||
| PCT/JP2004/010282 WO2005012245A1 (ja) | 2003-07-15 | 2004-07-13 | 新規ヘテロアリール誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE556051T1 true ATE556051T1 (de) | 2012-05-15 |
Family
ID=34113749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04747746T ATE556051T1 (de) | 2003-07-15 | 2004-07-13 | Neues heteroarylderivat |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7425642B2 (enExample) |
| EP (1) | EP1647546B1 (enExample) |
| JP (2) | JP4820169B2 (enExample) |
| KR (1) | KR101086654B1 (enExample) |
| CN (1) | CN100516041C (enExample) |
| AT (1) | ATE556051T1 (enExample) |
| CA (1) | CA2531064C (enExample) |
| ES (1) | ES2383895T3 (enExample) |
| MX (1) | MXPA06000539A (enExample) |
| TW (1) | TW200523249A (enExample) |
| WO (1) | WO2005012245A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1837329A4 (en) * | 2005-01-14 | 2009-08-05 | Dainippon Sumitomo Pharma Co | NEW HETEROARYL DERIVATIVE |
| US20060241073A1 (en) * | 2005-04-20 | 2006-10-26 | Wanders Ronaldus J A | Means and methods for counteracting fatty acid accumulation |
| CA2662112A1 (en) | 2006-09-05 | 2008-03-13 | Kyowa Hakko Kirin Co., Ltd. | Imidazole derivatives and their use as cannabinoid type 2 (cb2) receptor modulators |
| US20090054450A1 (en) * | 2007-06-19 | 2009-02-26 | Ironwood Pharmaceuticals, Inc. | Compositions and methods of use for treating or preventing lipid related disorders |
| KR20110083660A (ko) * | 2008-10-31 | 2011-07-20 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 당뇨병 치료제 |
| EP2412705B1 (en) * | 2009-03-26 | 2014-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel therapeutic agent for cognitive impairment |
| WO2011002012A1 (ja) * | 2009-07-01 | 2011-01-06 | 大日本住友製薬株式会社 | Sglt1阻害薬とインスリン抵抗性改善薬を組み合わせてなる医薬 |
| KR20120117905A (ko) | 2010-01-28 | 2012-10-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 프로테아좀 활성을 향상시키는 조성물 및 방법 |
| EP2593447B1 (de) | 2010-07-15 | 2016-08-17 | Bayer Intellectual Property GmbH | 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel |
| TR201906779T4 (tr) | 2011-05-12 | 2019-05-21 | Proteostasis Therapeutics Inc | Proteostaz regülatörleri. |
| US10266490B2 (en) * | 2012-03-16 | 2019-04-23 | Georgetown University | Radioprotector compounds |
| WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2752361A1 (de) * | 1977-11-24 | 1979-06-07 | Troponwerke Gmbh & Co Kg | Neue indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US6177443B1 (en) | 1997-03-07 | 2001-01-23 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use |
| EP0973778A1 (en) | 1997-03-07 | 2000-01-26 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
| US6911468B2 (en) | 2000-05-22 | 2005-06-28 | Takeda Chemical Industries, Ltd. | Tyrosine phosphatase inhibitors |
| JP2002121186A (ja) | 2000-05-22 | 2002-04-23 | Takeda Chem Ind Ltd | チロシンホスファターゼ阻害剤 |
| OA12292A (en) | 2000-06-26 | 2003-11-11 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents. |
| DE60227655D1 (de) * | 2001-04-19 | 2008-08-28 | Dainippon Sumitomo Pharma Co | Pyrrolderivat |
| JP2003171275A (ja) * | 2001-12-11 | 2003-06-17 | Sumitomo Pharmaceut Co Ltd | ＰＰＡＲδアゴニスト |
| AU2003284479A1 (en) | 2002-11-28 | 2004-06-18 | Sumitomo Pharmaceuticals Co., Ltd. | Novel heteroaryl derivative |
-
2004
- 2004-07-13 CA CA2531064A patent/CA2531064C/en not_active Expired - Fee Related
- 2004-07-13 JP JP2005512472A patent/JP4820169B2/ja not_active Expired - Fee Related
- 2004-07-13 WO PCT/JP2004/010282 patent/WO2005012245A1/ja not_active Ceased
- 2004-07-13 EP EP04747746A patent/EP1647546B1/en not_active Expired - Lifetime
- 2004-07-13 ES ES04747746T patent/ES2383895T3/es not_active Expired - Lifetime
- 2004-07-13 MX MXPA06000539A patent/MXPA06000539A/es active IP Right Grant
- 2004-07-13 AT AT04747746T patent/ATE556051T1/de active
- 2004-07-13 US US10/563,361 patent/US7425642B2/en not_active Expired - Fee Related
- 2004-07-13 KR KR1020067000907A patent/KR101086654B1/ko not_active Expired - Fee Related
- 2004-07-13 CN CNB2004800262352A patent/CN100516041C/zh not_active Expired - Fee Related
- 2004-07-15 TW TW093121149A patent/TW200523249A/zh not_active IP Right Cessation
-
2008
- 2008-07-15 US US12/173,792 patent/US20080306275A1/en not_active Abandoned
-
2011
- 2011-07-07 JP JP2011151138A patent/JP2011251974A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20080306275A1 (en) | 2008-12-11 |
| ES2383895T3 (es) | 2012-06-27 |
| WO2005012245A1 (ja) | 2005-02-10 |
| HK1087409A1 (en) | 2006-10-13 |
| CA2531064A1 (en) | 2005-02-10 |
| EP1647546B1 (en) | 2012-05-02 |
| MXPA06000539A (es) | 2006-03-30 |
| EP1647546A4 (en) | 2008-07-23 |
| US7425642B2 (en) | 2008-09-16 |
| JP4820169B2 (ja) | 2011-11-24 |
| KR101086654B1 (ko) | 2011-11-24 |
| JPWO2005012245A1 (ja) | 2006-09-14 |
| JP2011251974A (ja) | 2011-12-15 |
| US20060194857A1 (en) | 2006-08-31 |
| KR20060040681A (ko) | 2006-05-10 |
| CA2531064C (en) | 2012-05-22 |
| EP1647546A1 (en) | 2006-04-19 |
| TW200523249A (en) | 2005-07-16 |
| CN1849303A (zh) | 2006-10-18 |
| CN100516041C (zh) | 2009-07-22 |
| TWI331142B (enExample) | 2010-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1647546A4 (en) | NEW HETEROARYLE DERIVATIVE | |
| TW200510441A (en) | Novel compounds | |
| ATE448226T1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| CY1105797T1 (el) | Ν-αρυλ-2-οχαζολιδινονο-5-καρβοξαμιδια και παραγωγα αυτων και χρηση αυτων σαν αντιβιοτικα | |
| WO2008108386A1 (ja) | 医薬組成物 | |
| WO2004106343A3 (en) | Agelastatin derivatives of antitumour and gsk-3beta-inhibiting alkaloids | |
| DK1682138T3 (da) | Heterocykliske inhibitorer af MEK | |
| LU92113I2 (fr) | Perampanel et ses dérivés pharmaceutiquement acceptables (FYCOMPA) | |
| ATE492278T1 (de) | Verbindungen gegen entzündungen und immun- relevante verwendungen | |
| EA200600348A1 (ru) | Новые соединения | |
| EP1642880A4 (en) | PROTEIN INHIBITORS OF THE HSP90 FAMILY | |
| EP1394154A4 (en) | FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE | |
| DE60044342D1 (de) | Aminderivate | |
| NO20052907D0 (no) | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents. | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| EA200300392A1 (ru) | Производные пиперазина с мостиковой связью | |
| CY1105734T1 (el) | Nεα προ-φαρμακα του 1-μεθυλο-2-(4-αμιδινοφαινυλαμινομεθυλο)-βενζιμιδαζολ-5-υλιο-καρβοξυλικο οξυ-(ν-2-πυριδυλο-ν-2-υδροξυκαρβονυλαιθυλο)-αμιδιου, η παρασκευη και η χρησιμοποιηση τους ως φαρμακων | |
| ATE539124T1 (de) | Härtbare zusammensetzung, farbfilter vom negativtyp und dessen herstellungsverfahren | |
| ATE453389T1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
| EP1813270A4 (en) | PROTEIN INHIBITORS OF THE HSP90 FAMILY | |
| WO2004014917A3 (en) | Antitumoral analogs of lamellarins | |
| WO2006072000A3 (en) | Xanthurenic acid derivative pharmaceutical compositoins and methods related thereto | |
| EP1364945A4 (en) | BENZIMIDAZOLIDINONDERIVATE | |
| CA2386772A1 (en) | Pentacyclic taxane compound | |
| NO20063111L (no) | Fremgangsmate for fremstilling av tiazolpyrimidiner |